Valley Wealth Managers Inc. increased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 2.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,035,192 shares of the biopharmaceutical company’s stock after acquiring an additional 21,005 shares during the period. Pfizer makes up 1.5% of Valley Wealth Managers Inc.’s portfolio, making the stock its 18th biggest position. Valley Wealth Managers Inc.’s holdings in Pfizer were worth $29,524,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. grew its stake in shares of Pfizer by 15.7% in the second quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock worth $132,365,000 after purchasing an additional 745,213 shares in the last quarter. Handelsbanken Fonder AB raised its stake in shares of Pfizer by 10.4% during the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock valued at $59,295,000 after purchasing an additional 232,528 shares in the last quarter. Leuthold Group LLC acquired a new stake in Pfizer in the second quarter worth about $4,887,000. Park National Corp OH lifted its holdings in Pfizer by 332.1% in the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after purchasing an additional 186,053 shares during the period. Finally, 111 Capital bought a new position in Pfizer in the 2nd quarter valued at about $3,706,000. 68.36% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have commented on PFE. JPMorgan Chase & Co. boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday. Scotiabank raised their price objective on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Tuesday. BMO Capital Markets dropped their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. HSBC upped their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $28.72.
Pfizer Stock Performance
PFE opened at $28.27 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market cap of $161.14 billion, a PE ratio of 37.20, a P/E/G ratio of 1.87 and a beta of 0.32. The business has a fifty day simple moving average of $27.68 and a 200-day simple moving average of $26.50. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $29.21.
Pfizer (NYSE:PFE – Get Free Report) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The company had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $0.78 earnings per share. Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.
Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. Pfizer’s payout ratio is currently 226.32%.
Key Headlines Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Analyst support improved: JPMorgan raised its price target from $28 to $30 while maintaining a neutral rating, and Jefferies issued a buy rating. Cantor Fitzgerald also increased its target to $28, signaling some potential downside protection at current levels.
- Positive Sentiment: TUKYSA approval expands Pfizer’s oncology opportunity: The FDA approved TUKYSA in combination with trastuzumab and pertuzumab as a chemotherapy-free frontline maintenance treatment for certain patients with HER2-positive metastatic breast cancer. Moving the drug into an earlier line of treatment could broaden its commercial reach. FDA Backs Pfizer’s TUKYSA Combination
- Positive Sentiment: Pipeline progress adds longer-term support: Pfizer’s Phase 3 trial of tilrekimig, an asthma candidate, is advancing. Investors are also focused on oncology sales, biosimilars and the late-stage pipeline ahead of quarterly results. Tilrekimig Phase 3 Trial Update
- Positive Sentiment: Income and valuation appeal remain catalysts: Pfizer’s dividend announcement, roughly 6% yield and valuation below many large pharmaceutical peers continue to attract income and value-oriented investors. The company also has a history of earnings beats, with its latest reported quarter exceeding consensus estimates for both earnings and revenue.
- Neutral Sentiment: Investor attention is elevated: Pfizer was among heavily searched stocks, while broader biotechnology interest was helped by Moderna’s Nasdaq-100 inclusion. These factors may increase trading activity but do not directly change Pfizer’s fundamentals.
- Negative Sentiment: High yield raises risk concerns: Commentary warns that Pfizer’s unusually large dividend yield may reflect investor doubts about earnings, cash flow, debt and the durability of the payout. Sluggish revenue growth, a thin net margin and relatively low return on equity reinforce those concerns. Pfizer Dividend Yield Analysis
- Negative Sentiment: Cost-cutting highlights operational pressure: Pfizer plans to close a penicillin unit in Italy and eliminate about 330 jobs, underscoring efforts to improve efficiency amid a challenging growth outlook. Pfizer Italy Penicillin Unit Closure
Pfizer Profile
Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.
The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.
Featured Articles
- Five stocks we like better than Pfizer
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
